Product Information
BLISOVI FE 1.5-30 TABLET is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.1419 per EA under NDC 68180086913. Its NADAC has been published 48 times since Nov 5, 2025.
FDA first approved this application on Nov 18, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180086913
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA201585FDA Approved
11/18/2015
TE Code
AB
On Market Since
8/13/2025
Price Statistics
The NADAC for BLISOVI FE 1.5-30 TABLET has been published 48 times since Nov 5, 2025, and over the history we have for it it has declined 10.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1419 per EA |
|---|---|
| All-time high | $0.1575 (Nov 12, 2025) |
| All-time low | $0.1303 (Feb 18, 2026) |
| 52-week high | $0.1575 |
| 52-week low | $0.1303 |
| Median price | $0.1412 |
| Average price | $0.1415 |
| Largest weekly change | -5.5% (Jan 21, 2026) |
| Weeks tracked | 48 |
| Tracking since | Nov 5, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 9% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone acetate and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BLISOVI FE 1.5-30 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BLISOVI FE 1.5-30 TABLET, manufactured by Lupin Pharmaceuticals Inc., is $0.1419 per EA (NDC 68180086913), effective Sep 30, 2026.
How has the price of BLISOVI FE 1.5-30 TABLET changed over time?
Over the history we have for it, the NADAC for BLISOVI FE 1.5-30 TABLET has declined 10.0%. It has been tracked across 48 weekly CMS publications since Nov 5, 2025.
What are the highest and lowest recorded NADAC prices for BLISOVI FE 1.5-30 TABLET?
Since Nov 5, 2025, the NADAC for BLISOVI FE 1.5-30 TABLET has ranged from a low of $0.1303 (Feb 18, 2026) to a high of $0.1575 (Nov 12, 2025), with a median of $0.1412 per EA.
Are there cheaper alternatives to BLISOVI FE 1.5-30 TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BLISOVI FE 1-20 TABLET, is $0.1287 per EA — about 9% below BLISOVI FE 1.5-30 TABLET.
Who manufactures BLISOVI FE 1.5-30 TABLET?
BLISOVI FE 1.5-30 TABLET (NDC 68180086913) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.